CCORF analyst Whitney Ijem maintains $Vertex Pharmaceuticals (VRTX.US)$ with a sell rating, and adjusts the target price from $361 to $408.
According to TipRanks data, the analyst has a success rate of 45.7% and a total average return of 5.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Following Vertex Pharmaceuticals' third-quarter results surpassing consensus estimates and the upward adjustment of its 2024 revenue forecast by approximately 1% at the midpoint, anticipation is building for the forthcoming suzetrigine Phase 2 lumbosacral radiculopathy data, which is projected to be released by the end of the year.
The company's robust performance in cystic fibrosis, which surpassed expectations, underscores the ongoing strength of its central business line, potentially supporting the stock's elevated valuation. However, caution is advised as the approach to FY25 might present more complexities compared to FY24. The forthcoming LSR data on suzetregine is anticipated to meet efficacy expectations, though it may not generate significant enthusiasm. Additionally, launches in the acute pain segment and for Casgevy are expected to progress at a gradual pace.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
CCORF分析師Whitney Ijem維持$福泰製藥 (VRTX.US)$賣出評級，並將目標價從361美元上調至408美元。
根據TipRanks數據顯示，該分析師近一年總勝率為45.7%，總平均回報率為5.0%。
此外，綜合報道，$福泰製藥 (VRTX.US)$近期主要分析師觀點如下：
福泰製藥第三季度業績超過共識預期，2024年營業收入預測在中點處調整約1%，市場對即將發佈的蘇瑟曲嗪二期腰骶神經根病數據的期待正在增加，預計將於年底發佈。
公司在囊性纖維化領域表現強勁，超出預期，突顯其核心業務線持續強勁，可能支撐股票的高估值。然而，鑑於2025財年的運營策略可能比2024財年更爲複雜，謹慎仍然是必要的。即將發佈的若曲替吉星的腰椎根病數據有望符合功效預期，但可能不會引發過多熱情。此外，急性疼痛領域和卡斯吉威的推出預計將以逐步的速度進行。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
